Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to ...

Shares of Scholar Rock climbed after the company disclosed what it called positive results from a Phase 2 study assessing its drug for weight loss. Shares rose 12% to $35.01 in pre-market trading ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly. Scholar Rock, a biopharma company ...